Impax to divest 10 products amid acquisition by Amneal

The Federal Trade Commission (FTC) is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

FTC rules Impax received illegal payments to block pain reliever generic

1 April 2019 Pharmaceutical company Impax Laboratories engaged in illegal pay-for-delay settlements to stop a generic version of one of its medications from entering the market, the US Federal Trade Commission has ruled.

Americas

FTC approves Amneal’s $1.45bn acquisition of Impax

11 July 2018 The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.

Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

19 October 2017 Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

More on this story

Big Pharma

FTC rules Impax received illegal payments to block pain reliever generic

Americas

FTC approves Amneal’s $1.45bn acquisition of Impax

11 July 2018 The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.

Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

19 October 2017 Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

More on this story

Big Pharma

FTC rules Impax received illegal payments to block pain reliever generic

Americas

FTC approves Amneal’s $1.45bn acquisition of Impax

11 July 2018 The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.

Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

19 October 2017 Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

Impax to divest 10 products amid acquisition by Amneal

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features